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Abstracts / Osteoarthritis and Cartilage 22 (2014) S1–S6 S5a variant near the NCOA3 (nuclear receptor coactivator 3) gene and an
199-candidate gene meta-analysis of GWAS demonstrated association
only between COL11A1 and VEGF genes and hip OA. In addition, the
effect of the FTO variant on OA risk was found to be mediated through
body mass index. In OA genomics, four trans-acting factors were
identiﬁed that bind to GDF5 and regulate its expression via the OA
susceptibility locus rs143383. Gene expression microarray studies in OA
synovium showed elevation of collagens and cross-linking enzymes
(COL1A1, COL5A1, PLOD2, LOX and TIMP1) responsive to TGF-b and also
differential expression pattern between different areas of the osteo-
arthritic synovial membrane. Microarray analysis in peripheral blood
demonstrated differentially expressed genes involved in apoptotic
pathways between OA patients and healthy controls. Furthermore, gene
expression proﬁling in OA subchondral bone revealed differentially
expressed genes involved in cartilage and bone development and OA
pathogenesis. In epigenetics, a number of studies identiﬁed the role of
several microRNAs (miRs) in regulation of gene expression in chon-
drocytes and highlighted their use as potential drug targets. Among
them, miR-125 was implicated in ADAMTS-4 regulation, miR-127b in
MMP-13 regulation and IL-1b induced catabolic effects, miR-1247 was
shown to directly target SOX9 and overexpression of hsa-miR-148a in
OA chondrocytes inhibited hypertrophic differentiation and increased
COL2A1 production. Future studies must focus on the integration of
genetics and genomics for the identiﬁcation of signaling pathways and
regulatory networks responsible for OA development.
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YEAR IN REVIEW - BIOMARKERS IN OA
F.J. Blanco. INIBIC-CHUAC, A Coru~na, Spain
Currently, OA diagnosis is mainly symptomatic, resting on the
description of pain symptoms, stiffness of the affected joints, and
radiography, which has been the reference technique to determine the
grade of joint destruction. This is of key importance, since radiography
provides only indirect information about the joint tissue and it has poor
sensitivity to detect changes. This lack of diagnostic tools is especially
important in OA, since there is currently no effective therapy for this
disease. A major pursue in OA research relies in the deﬁnition of early
diagnostic strategies, which would also aid to enable an accurate
monitoring of the progression of the disease. OA remains silent at its
initial stages in most patients, and there is already an extensive dete-
rioration of cartilage at the time of diagnosis. All this background is the
reason for the substantial interest in ﬁnding new speciﬁc biological
markers of osteoarthritis that will facilitate not only early diagnosis of
joint destruction (which will enable early interventions intended to
slow the progression of the disease), but also disease prognosis or
evolution studies (which will facilitate the development of alternative
therapeutic strategies). Over the years there have been proposed a
series of biochemical markers which may reﬂect the synthesis or deg-
radation of the three main joint tissues (cartilage, synovial membrane
and bone), and this list is continuously expanding. However, despite the
active research in this ﬁeld, no single biomarker stands out as the gold
standard or is sufﬁciently validated and qualiﬁed for its systematic use
in OA diagnosis or anti-OA drug development. The most promising
diagnostic approach would be the study of combinations of biomarkers.
New multiplexed approaches have emerged in the recent years for the
identiﬁcation and veriﬁcation of novel OA biomarkers, employing
genomics, proteomics and metabolomics tools. In this review I will
present the most relevant proteomic and metabolomics results pub-
lished since April 2013 to April 2014 focused in the early and con-
solidated diagnosis of OA, in to predict how it will develop, or respond
to therapy.
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THE YEAR IN REVIEW: REGENERATIVE MEDICINE
G.J. van Osch. Erasmus MC, Rotterdam, Netherlands
Regenerative medicine is an emerging area that will inﬂuence the
treatment of joint diseases in the future. It involves the use of bio-
materials, cell therapy, and bioactive factors such as growth factors,
drugs and small molecules to regenerate damaged tissues. This multi-
disciplinary ﬁeld is extremely active, with rapid development of new
technologies that emerge from basic sciences as well as by the
increasing number of clinical studies of ever increasing quality. Apubmed search revealed over 2000 hits in the past year on regener-
ation/repair of joint tissues (excluding bone regeneration in its own
right) and over 25 new clinical trials on joint regeneration therapies
were registered. This “year in review”will highlight a personal selection
of promising studies in biomaterials, stem cell biology and the trans-
lation from the lab to the clinic published in the past year and will
inform on the direction in which this ﬁeld is moving.
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OSTEOARTHRITIS YEAR 2014 IN REVIEW: CLINICAL
G.A. Hawker. Women’s Coll. Hosp., Toronto, ON, Canada
A systematic literature review was conducted using PubMed for the
period between April 1, 2013 and March 31, 2014. Research articles that
focused on the epidemiology, clinical management - both non-phar-
macologic and pharmacologic - or access to and outcomes of treatment
for people with osteoarthritis were reviewed. Selected articles in these
areas are discussed in this narrative review article.
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OSTEOARTHRITIS YEAR IN REVIEW: REHABILITATION AND
OUTCOMES
M. Maly. McMaster Univ., Hamilton, ON, Canada
Purpose: The purpose of this review will be to highlight research
studies examining rehabilitation for hip and knee osteoarthritis, as well
as the outcomes used to assess treatment effectiveness, published
between January and December 2013.
Methods: A systematic literature was performed in Medline, CIHAHL
and Embase databases from January 1, 2013 to December 12, 2013. Key
words used in the searches included osteoarthritis, knee; osteoarthritis,
hip; rehabilitation; physical therapy modalities; physical therapy;
physiotherapy; and exercise. The search was limited to 2013, human
studies and English. Rehabilitation intervention studies included in the
review were prospective controlled designs that enrolled study par-
ticipants with a diagnosis of knee or hip osteoarthritis. Uncontrolled,
qualitative and retrospective studies, protocols, as well as reviews,
meta-analyses and case studies were excluded. Studies of outcomes
after surgical interventions, oral or injectable medications, and neu-
traceuticals were also excluded. Publication titles and abstracts were
reviewed for inclusion by both authors. Discrepancies for inclusion
were discussed and full papers reviewed to reach agreement on
inclusion. Papers were evaluated for quality of evidence using the
Grading of Recommendations Assessment, Development and Evalua-
tion (GRADE) system by both authors. This system rates the quality of
evidence as high (A), moderate (B), low (C), and very low (D) based on
study limitations, consistency, directness, precision and publication
bias. The authors reached consensus on quality of evidence ratings for
each article.
Results: Of 502 titles reviewed, 36 studies were identiﬁed for inclusion.
Of these 36 papers, only two papers were dedicated to hip OA. Five
studies included participants with both knee and hip OA and 29 studies
included only knee OA. An assessment of the quality of evidence
revealed that articles were of high (n¼2), moderate (n¼14), low (n¼10)
and very low (n¼10) quality. Papers were grouped based on outcome
measures: disease/tissue markers, pain, self-reported physical function,
mobility performance, general health, and participation/quality of life.
Interventions reﬂected exercise (strengthening, walking, yoga, gaming),
physical agents and electrotherapy (ultrasound, phonophoresis, short
wave diathermy, transcutaneous electrical nerve stimulation, neuro-
muscular electrical stimulation), manual therapy (mobilizations, trac-
tion), Chinese medicine (acupuncture, meridians) and other (pain
coping, counseling, whole body vibration). High quality studies high-
lighted rehabilitation strategies that improved markers of OA disease
and general health, in addition to improvements in clinical outcomes,
over both the short term and long term. For example, in a randomized,
double-blind, controlled trial, phonophoresis was superior to tradi-
tional ultrasound for symptomatic knee OA in reducing pain over 2
weeks of therapy. A randomized controlled trial (n¼454) compared the
effectiveness of an intensive diet-induced weight-loss, exercise, or diet-
induced weight loss combinedwith exercise onmechanistic and clinical
outcomes in knee OA over a follow-up period of 6 and 18 months. After
18 months, data from 399 participants demonstrated that diet com-
bined with exercise and diet alone resulted in greater declines in body
